RAD50 and central nervous system cancer: In the present study, the peak enrichment of E2F1 in the promoter regions of TP53, CHEK1, CHEK2, RAD50 and RAD51, which were predicted on JASPAR datasets, was significantly downregulated in TMZ-resistant glioma cells with BIP-MPC-NP treatment.